<DOC>
	<DOC>NCT01783951</DOC>
	<brief_summary>The purpose of this study is to evaluate the antitumor effect and safety of clinical effectiveness S-1 plus dendritic cell activated Cytokine induced killer treatment (DC-CIK) for advanced gastric cancer.</brief_summary>
	<brief_title>Study of S-1 Plus DC-CIK for Patients With Advanced Gastric Cancer</brief_title>
	<detailed_description />
	<mesh_term>Stomach Neoplasms</mesh_term>
	<criteria>Histologically/cytologically confirmed recurrent or metastatic gastric or esophagogastric junctional adenocarcinoma Between 18 and 80 years old Capable of oral intake Measurable disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST) criteria Karnofsky Performance Status (KPS) ≥ 70% Normal functions of heart, lung and bone marrow Adequate hematological profile： Hemoglobin ≥ 9.0 g/dL Absolute granulocyte count ≥ 1,500/mm3 Platelet count ≥ 100,000/mm3 Adequate hepatic function Total bilirubin level≤ 3.0 times the upper limit of normal (ULN) Transaminases AST (SGOT) and ALT (SGPT) ≤ 2.5 times ULN Adequate renal function(normal serum creatinine level) A life expectancy≥ 2 months Informed consent signed Current enrollment in another clinical study with an investigational agent. Patients participating in surveys or observational studies are eligible to participate in this study Any radiotherapy or surgery within the previous 4 weeks Symptomatic brain metastasis not controlled by corticosteroids Bone marrow metastasis Active infection Serious complications Receiving a concomitant treatment with drugs interacting with S1. The following drugs are prohibited because there may be an interaction with S1: phenytoin, potassium warfarin , flucytosine, cimetidine and folinic acid. Pregnant or lactation women, or women with known or suspected pregnancy and men who want let to pregnancy Ineligible for the study at the discretion of investigators</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Gastric cancer</keyword>
	<keyword>S-1</keyword>
	<keyword>DC-CIK</keyword>
</DOC>